Co-Diagnostics earnings date
Want to see CODX full AI Analyst Report?
Co-Diagnostics (CODX) Q2 2026 Earnings Report
CODX Q2 2026 EPS Results
- Actual EPS
- -$1.46
- Consensus EPS
- ―
- Beat/Miss
- ―
- One Year Ago EPS
- -$6.90
CODX Q2 2026 Revenue Results
- Actual Revenue
- $166.13K
- Expected Revenue
- ―
- Beat/Miss
- ―
- YoY Revenue Growth
- +1.98%
Earnings Announcement Details
- Quarter
- Q2 2026
- Date
- 08/13/2026
- Time
- After Close
- Conference Call
- Thursday, August 13, 2026
Co-Diagnostics's next earnings date is estimated for March 25, 2027, based on past reporting schedules.
Q2 2026 Earnings Call Audio
Q2 2026 Earnings Slide Deck
No slide deck is available for this earnings event.
Q2 2026 Earnings Call Summary
The call conveyed meaningful operational and regulatory progress — including a dual FDA submission for an upper respiratory multiplex assay, >1,400-patient clinical enrollment, >10,000 analytical PCR runs, TB program advancement toward ERPD, a blood-based Ebola proof-of-concept, strengthened international manufacturing partnerships, and reduced operating expenses that improved net loss and adjusted EBITDA. However, these positives are counterbalanced by a very low revenue base ($166K), a steep decline in cash to $3.6M (≈70% drop), continued operating losses, and materially reduced total assets. While execution milestones materially de-risk the technology and regulatory path, the company faces near-term liquidity and commercialization scaling risks.
Management's guidance emphasized continued near‑term operating losses while advancing toward commercialization and prioritizing regulatory, clinical, commercial and platform milestones; Q2 FY2026 results included revenue of $166k (vs. $163k), cost of revenue $45k, gross profit ≈$121k (vs. $131k), operating expenses $6.3M (vs. $8.2M), R&D $4.2M (vs. $4.7M), sales & marketing $467k (vs. $610k), G&A $1.5M (vs. $2.6M), net loss $6.3M or $1.46 per share (vs. $7.7M or $7.00), adjusted EBITDA loss $5.8M (vs. $7.2M), cash $3.6M (vs. $11.9M at 2025 year‑end), total assets $16.6M and liabilities $3.9M; operational metrics and milestones include 27 analytical studies and >10,000 upper‑respiratory PCR runs, enrollment of >1,400 symptomatic patients across 9 U.S. sites, submission of a dual 510(k)/CLIA‑waived Flu A/B+RSV application, planned TB submissions to India’s CDSCO and WHO ERPD later this year, a C‑CAMP request for 200 Bundibugyo tests, cloud expansion to India and Saudi Arabia, and ongoing evaluation of equity, debt, strategic transactions and nondilutive funding to support these objectives.
- Regulatory Submission — Dual 510(k) and CLIA-waived for Flu A/B & RSVSubmitted a dual 510(k) and CLIA-waived application to FDA for the Flu A/B and RSV assay on the Co-Dx PCR platform; follows completion of analytical and clinical performance studies (27 analytical studies, >10,000 PCR runs) and a clinical study enrolling >1,400 symptomatic patients across 9 U.S. sites.
- Progress on Tuberculosis Program and ERPD PathwayAdvancing TB clinical studies in India on the CoSara PCR Pro instrument and CoSara PCR MTB test with planned submissions to India's CDSCO and targeting WHO ERPD assessment later this year; leverages local manufacturing and NGO-supported validation costs.
- Platform Expansion — Ebola & Blood-Based Assay Proof of ConceptCompleted proof-of-concept for a Bundibugyo (Ebola) assay using direct-from-plasma on the Co-Dx PCR Pro instrument (first blood-based assay), and responded to a C-CAMP request for 200 tests, demonstrating platform flexibility beyond swab-based respiratory testing.
- Commercial & Manufacturing Partnerships — CoSara and CoMiraStrengthened international commercialization via CoSara (India) and CoMira (Saudi Arabia); hosted CoMira execs for technology transfer and unveiled an automated manufacturing line to support localized production and scale across Middle East/North Africa.
- Digital & Connected Platform DevelopmentInvested in a connected ecosystem (mobile app + secure cloud) and began deployment in target regions (India, Saudi Arabia), designed for remote system management, real-time data access, and potential AI-enabled capabilities to support decentralized testing and population-level insights.
- Commercial Traction for Vector SmartExpanded customer footprint for Vector Smart across U.S. mosquito abatement districts, enabling in-house molecular testing and reduced turnaround times — demonstrating applicability beyond clinical diagnostics.
- Operating Expense Reductions and Improved Profitability MetricsTotal operating expenses declined to $6.3M from $8.2M year-over-year (≈23.2% reduction). Net loss improved to $6.3M ($1.46 per share) from $7.7M ($7.00 per share) year-over-year (≈18.2% improvement). Adjusted EBITDA loss improved to $5.8M from $7.2M (≈19.4% improvement).
CODX Earnings History
| Report Date | Fiscal Quarter | Forecast / EPS | Last Year's EPS | EPS YoY Change | Press Release |
|---|---|---|---|---|---|
| Mar 25, 2027 | 2026 (Q4) | -0.27- | -16.35 | ― | ― |
| Nov 10, 2026 | 2026 (Q3) | -1.25-1.01 | -4.8 | 78.96% (+3.79) | |
| Aug 13, 2026 | 2026 (Q2) | ―-1.46 | -6.9 | 78.84% (+5.44) | |
| May 14, 2026 | 2026 (Q1) | ―-4.06 | -7.2 | 43.61% (+3.14) | |
| Mar 31, 2026 | 2025 (Q4) | -3.60-4.06 | -7.2 | 43.61% (+3.14) | |
| Nov 13, 2025 | 2025 (Q3) | -5.70-4.80 | -9.6 | 50.00% (+4.80) | |
| Aug 14, 2025 | 2025 (Q2) | -7.50-6.90 | -7.5 | 8.00% (+0.60) | |
| May 08, 2025 | 2025 (Q1) | -8.10-7.20 | -9.3 | 22.58% (+2.10) | |
| Mar 27, 2025 | 2024 (Q4) | -10.20-10.80 | -14.82 | 27.13% (+4.02) | |
| Nov 07, 2024 | 2024 (Q3) | -9.90-9.60 | -6 | -60.00% (-3.60) |
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

